1Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336-41.
2Takeuchi F, Serizawa M, Yamamoto K, Fujisawa T, Nakashima E, Ohnaka K, etal. Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes 2009,58: 1690-9.
3Hinohara K, Nakajima T, Sasaoka T, Sawabe M, Lee BS, Ban J, et al. Replication studies for the association of psma6 polymorphism with coronary artery disease in east asian populations. J Hum Genet 2009; 54: 248-51.
4Wu Y, Li H, Loos R J, Yu Z, Ye X, Chen L, et al. Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC3OA8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes 2008; 57: 2834-42.
5Christiansen J, Kolte AM, Hansen TO, Nielsen FC. Igf2 mrna-binding protein 2: Biological function and putative role in type 2 diabetes. J Mol Endocrinol 2009; 43: 187-95.
6Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor ii mrna-binding proteins represses translation in late development. Mol Cell Biol 1999; 19: 1262-70.
7Ng MC, Park KS, Oh B, Tam CH, Cho YM, Shin HD, et al.Implication of genetic variants near TCF7L2, SLC3OA8, HHEX, CDKAL1, CDKN2A/ B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes 2008; 57: 2226-33.
8Groenewoud M J, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine R J, et al. Variants of cdkall and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 2008; 51: 1659-63.
9Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41: 471-83.
10Papa G, Fedele V, Rizzo MR, Fioravanti M, Leotta C, Solerte SB, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. Diabetes Care 2006; 29: 1918-20.
